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Abstract
Shortages of medicines and vaccines have been reported in countries of all income levels in recent years. Shortages
can result from one or multiple causes, including shortages of raw materials, manufacturing capacity problems,
industry consolidation, marketing practices, and procurement and supply chain management. Existing approaches
to mitigate shortages include advance notice systems managed through medicine regulatory authorities, special
programmes that track medicines, and interventions to improve efficiency of the medicine supply chain. Redistribution
of supplies at the national level can mitigate some shortages in the short term. International redistribution and
exceptional regulatory approvals may be used in limited circumstances, with the understanding that such approaches
are complex and may introduce cost and quality risks. If it is necessary to prioritise patients to receive a medicine that is
in shortage, evidence-based practice should be used to ensure optimal allocation. Important steps in reducing
medicine shortages and their impact include identifying medicines that are most at risk, developing reporting systems
to share information on current and emerging shortages, and improving data from medicine supply chains.
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Background
Shortages of medicines and vaccines have been reported
in countries of all income levels in recent years. For ex-
ample, in 2013, Kerala, India, faced a shortage of 130
medicines on the state’s Essential Medicines List and
Rationalized Drug List when suppliers did not respond
to state tenders [1]. Chemotherapeutic agents, generic
injectables, and epilepsy medications continue to be in
short supply across North America for reasons ranging
from manufacturing problems to low commercial interest
[2, 3]. The BCG vaccine, critical in childhood immunization
and also in the treatment of bladder cancer, has been in
shortage across multiple markets since 2012 due to manu-
facturing quality problems combined with high demand [4].
Medicine shortages result from single or multiple
causes, ranging from problems at the production level to
weak supply chains that prevent medicines from reach-
ing points of care. Irrespective of the causes, shortages
lead to increased costs for health systems. The additional
labour cost of responding to shortages in the United
States was estimated at US$ 216 million per annum by
Kaakeh et al. [5]. Other costs to health systems include
higher prices of substitute medicines, as well as costs of
treating adverse reactions, medication errors, and conse-
quences of delayed therapy [6]. Shortages may also lead
to prescribers and dispensers substituting medicines that
are not clinically appropriate.
In this article, we outline the causes of shortages and
the existing solutions to mitigate these, as well as the
ethical considerations and the actions taken by the global
community to manage shortages.
Reasons for shortages
Shortages result from one or more causes [7], including
manufacturing issues, acute healthcare needs, external
political and economic factors, or marketing, procure-
ment, and supply chain management practices. Examples
of manufacturing issues resulting in shortages include a
lack of raw materials, limited manufacturing capacity, or
product quality problems resulting in more stringent in-
spections and plant closures. Health emergencies, such
as disasters and disease outbreaks, can also trigger short-
ages due to unexpected and large surges in demand [7].
Similarly, changes in recommended clinical practices
can dramatically impact availability; for example, when
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the United Kingdom recommended inclusion of the
meningitis B vaccine in the childhood immunization
programme in 2015, a surge in demand led to a shortage
of supply [8].
Industry consolidation has led to fewer manufacturers
for older, often less profitable medicines [9]. Consolida-
tions may also lead to new regulatory applications and
transfers in marketing authorization, with resulting re-
quirements for regulatory assessment [10]. Incomplete
or delayed regulatory submissions may delay marketing
authorization and potentially lead to national supply
shortages. Factors such as poor financial incentives for
manufacturers, changes in reimbursement, changes in
regulatory requirements, and costs required to correct
manufacturing errors can decrease the availability of
medicines [9]. If profit margins are low, for example due
to either competition or price controls, the expenses re-
quired to ensure good manufacturing practices [11] may
not be covered and, therefore, keeping production lines
in operation may not be viable [12].
At present, there is no global system to capture data
or trends on shortages, which compromises efforts to re-
spond to or prevent them; some national early warning
systems do exist, but only from a limited number of
countries and programs. Additionally, the criteria for
what constitutes a medicine at high risk of shortage may
differ from region to region.
Management of shortages
Efforts to avoid and mitigate shortages include advance
notice systems to national medicines regulatory author-
ities (NMRAs), as well as special initiatives that monitor
stock levels of specific medicines. Data from medicine
supply chains are important for maintaining and fore-
casting supply. Advance notice systems with NMRAs
exist mainly in high-income markets and require manu-
facturers to advise them regarding impending shortages
[13]. Responses from NMRAs include identifying clinically
acceptable substitute medicines, providing notifications to
prescribers and dispensers, facilitating exceptional market
authorizations for other producers and, in some cases,
identifying other manufacturing capacities; however,
NMRAs do not have legislative authority to compel a
manufacturer to produce.
Professional associations, such as the American Society
of Health-System Pharmacists (ASHSP) and the Associ-
ation Africaine des Centrales d’Achats de Médicaments
Essentiels (ACAME), an association of central medical
stores across Africa, have mechanisms for sharing infor-
mation among members. The ASHSP collates and reports
national wholesale level shortages and publishes these
online [14]. Similarly, ACAME shares information on
pricing, procurement sources, availability, quality, and
technical specifications of medicines. One of its aims is
to coordinate demand across countries as a means of
reducing shortages at wholesale and supply chain levels
in the region [15]. These types of systems are also useful
in managing shortages, for example, by identifying alterna-
tive sources of products. However, this information comes
primarily from procurement and logistics management in-
formation systems, which may not immediately signal that
a shortage is caused by a manufacturing problem.
Data from the medicines supply chain are useful,
particularly for analysing trends and maintaining ap-
propriate supply levels to prevent avoidable shortages
[16]. Still, challenges with unavailable or unreliable supply
chain data have persisted for decades [17]. Monitoring the
supply chain may also allow countries to redistribute
medicines across warehouses or health facilities, as well
as to manage emergency orders when necessary. In theory,
countries could work together to mitigate shortages by
sharing or redistributing inventories; however, this option
would require regulatory agreements and may introduce
extra costs and quality risks [7]. Illegal diversion of stock
may create or exacerbate shortages in the originating
country, distort overall demand, and may result in the
introduction of substandard, spurious, falsely labelled, fal-
sified, or counterfeit (SSFFC) products into the supply
chain [18, 19].
Ethical approaches to managing medicines in short
supply can be complicated, as seen, for example, in the
inactivated polio vaccine and cancer therapies shortages
across multiple countries [20, 21]. An ethical framework
to ensure equity, fairness and public health interest is
therefore important in managing a shortage [22]. For
example, the allocation of medicines may be guided by
evidence that prioritizes high-risk groups [23] or, in
other cases, to groups that would have greater therapeutic
benefit.
Future directions and conclusions
Addressing medicine and vaccine shortages is a multi-
faceted issue. Ensuring access to essential medicines
and health technologies is a target of the Sustainable
Development Goals [24]. In addition to improving the
quality and scope of a country’s national supply chain
data, international collaboration is required in order to
manage large-scale shortages. Further, definitions of short-
ages and stock-outs must be harmonized to develop effect-
ive cross-country interventions. Similarly, medicines most
at risk of global shortages, especially those without clinically
acceptable substitutes, must be identified and prioritized
for global action. With an improved understanding of the
gaps in current information on the causes of shortages and
noting the benefits of global communication, countries may
also consider supporting the development of a global early-
warning shortage notification system to identify substitutes,
alternative suppliers, or other mitigation measures. In the
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context of minimizing the risk of SSFFC, countries may
consider implementing ‘track and trace’ systems for
medicines. These types of mechanisms promote robust
data collection and can strengthen good governance
and accountability in the pharmaceutical sector. It is
equally important that countries promote the optimal
use of medicines to ensure accurate and clinically ap-
propriate demand. Ultimately, policy mechanisms and
harmonization efforts should emphasize their support
for good manufacturing practices, appropriate supply
chain management and security, and the coordination
of strategies for the notification of shortages.
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